Praxis Precision Medicines to Participate in Upcoming April Conferences
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced its participation in two major investor conferences in April 2025.
The company will present a corporate overview at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 11:00 a.m. EDT, which will be available via webcast. Additionally, Praxis management will attend the Piper Sandler Spring Biopharma Symposium in Boston on April 17, 2025, offering one-on-one meeting opportunities.
Investors interested in meetings should contact their Needham or Piper Sandler representatives. Webcast replays will be accessible through the company's website's 'Events & Presentations' page for 90 days.
Praxis Precision Medicines (NASDAQ: PRAX), una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per i disturbi del sistema nervoso centrale, ha annunciato la sua partecipazione a due importanti conferenze per investitori nell'aprile 2025.
La società presenterà una panoramica aziendale alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute il 7 aprile 2025, alle 11:00 EDT, che sarà disponibile tramite webcast. Inoltre, il management di Praxis parteciperà al Piper Sandler Spring Biopharma Symposium a Boston il 17 aprile 2025, offrendo opportunità di incontri one-to-one.
Gli investitori interessati a incontri dovrebbero contattare i loro rappresentanti di Needham o Piper Sandler. Le registrazioni dei webcast saranno accessibili attraverso la pagina 'Eventi e Presentazioni' del sito web dell'azienda per 90 giorni.
Praxis Precision Medicines (NASDAQ: PRAX), una compañía biofarmacéutica en etapa clínica centrada en desarrollar terapias para trastornos del sistema nervioso central, ha anunciado su participación en dos importantes conferencias para inversores en abril de 2025.
La compañía presentará una visión general corporativa en la 24ª Conferencia Virtual Anual de Salud de Needham el 7 de abril de 2025, a las 11:00 a.m. EDT, que estará disponible a través de una transmisión en vivo. Además, la dirección de Praxis asistirá al Piper Sandler Spring Biopharma Symposium en Boston el 17 de abril de 2025, ofreciendo oportunidades de reuniones uno a uno.
Los inversores interesados en reuniones deben contactar a sus representantes de Needham o Piper Sandler. Las repeticiones de la transmisión en vivo estarán accesibles a través de la página 'Eventos y Presentaciones' del sitio web de la compañía durante 90 días.
프랙시스 프리시전 메디슨스 (NASDAQ: PRAX), CNS 질환 치료제 개발에 집중하는 임상 단계의 생명공학 회사가 2025년 4월 두 개의 주요 투자자 회의에 참여한다고 발표했습니다.
회사는 2025년 4월 7일 오전 11시 EDT에 제24회 니드햄 가상 헬스케어 컨퍼런스에서 기업 개요를 발표하며, 이는 웹캐스트를 통해 제공될 예정입니다. 또한, 프랙시스 경영진은 2025년 4월 17일 보스턴에서 열리는 파이퍼 샌들러 스프링 바이오파마 심포지엄에 참석하여 일대일 미팅 기회를 제공합니다.
미팅에 관심 있는 투자자는 니드햄 또는 파이퍼 샌들러의 담당자에게 연락해야 합니다. 웹캐스트 재방송은 회사 웹사이트의 '이벤트 및 발표' 페이지를 통해 90일 동안 접근할 수 있습니다.
Praxis Precision Medicines (NASDAQ: PRAX), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies pour les troubles du système nerveux central, a annoncé sa participation à deux grandes conférences pour investisseurs en avril 2025.
L'entreprise présentera un aperçu de l'entreprise lors de la 24ème Conférence Virtuelle Annuelle de Needham sur la Santé le 7 avril 2025 à 11h00 EDT, qui sera disponible par webcast. De plus, la direction de Praxis assistera au Piper Sandler Spring Biopharma Symposium à Boston le 17 avril 2025, offrant des opportunités de réunions individuelles.
Les investisseurs intéressés par des réunions doivent contacter leurs représentants de Needham ou Piper Sandler. Les rediffusions des webcasts seront accessibles via la page 'Événements et Présentations' du site web de l'entreprise pendant 90 jours.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für Erkrankungen des zentralen Nervensystems konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im April 2025 angekündigt.
Das Unternehmen wird am 7. April 2025 um 11:00 Uhr EDT eine Unternehmensübersicht auf der 24. jährlichen virtuellen Gesundheitskonferenz von Needham präsentieren, die über einen Webcast verfügbar sein wird. Darüber hinaus wird das Management von Praxis am 17. April 2025 am Piper Sandler Spring Biopharma Symposium in Boston teilnehmen und Möglichkeiten für persönliche Meetings anbieten.
Investoren, die an Meetings interessiert sind, sollten ihre Vertreter von Needham oder Piper Sandler kontaktieren. Aufzeichnungen des Webcasts sind 90 Tage lang über die Seite 'Veranstaltungen & Präsentationen' auf der Website des Unternehmens zugänglich.
- None.
- None.
BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences this April:
- Praxis management will be presenting a corporate overview at the 24th Annual Needham Virtual Healthcare Conference, taking place virtually on Monday, April 7, 2025 at 11:00a.m. EDT. A live webcast of the event will be available through this link.
- Praxis management will also be participating in the Piper Sandler Spring Biopharma Symposium, taking place at One Boston Place in Boston on Thursday, April 17, 2025.
The Company will be available for one-on-one meetings during both events. Interested investors should contact their respective Needham and/or Piper Sandler representatives to request meetings.
Replays of the webcasted events will also be available through the “Events & Presentations” page under the “Investors + Media” section of the company’s website for 90 days.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
When is Praxis Precision Medicines presenting at the Needham Healthcare Conference in 2025?
Where can investors watch Praxis Precision Medicines' April 2025 conference presentations?
Which investor conferences is PRAX attending in April 2025?
How can investors schedule one-on-one meetings with Praxis management at the April 2025 conferences?
